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Abstract. Patients with eczema experienced significant changes in
systemic immunity indexes that indicate the presence of  immu-
nomediated mechanisms of the development involving T link immu-
nity, with multi-directional changes of subpopulations of T lympho-
cytes in patients with different clinical forms of dermatitis. It was
established that more significant changes in rates of systemic
immunity were observed in patients suffering from eczema with
advanced skin lesions and prolonged (over 3 years) course  of
dermatosis which justifies the advisability of administering adequate,
immunocorrective therapy for such patients.
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Introduction
Eczema is one of the most common allergic skin
diseases, which is registered in 20-40% of der-
matological patients [2,10]. The increase of a number
of common and complicated forms, chronic course
of dermatosis with frequent relapses and develop-
ment of resistance to basic therapy in patients, which
reduces their quality of life and social activity, sug-
gests important medical and social significance of
this dermatosis [3,12].
According to current data, the pathogenesis of
eczema is complex and multifactorial. Eczema ap-
pears under the influence of both exogenous factors
and disorders of immune response, neurohumoral and
endocrine regulation, genetic determinism, related
diseases of the digestive system, leading to metabolic
disorders, autosensitisation etc. [1, 3,11].
It has been established that the changes in sys-
temic immunity plays an important role in the de-
velopment of  dermatoses and their becoming chronic
[4,5], but the role of immune mechanisms in the
pathogenesis of eczema is not fully elucidated, since
data on cellular and humoral immune system is often
ambiguous, contradictory, indicating their diverse
disorders in chronic dermatoses [6,9]. In this con-
nection determining systemic immunity condition in
patients with eczema suffering from different derma-
tosis clinical course is urgent.
Objective
To determine and analyse the condition of sys-
temic immunity indices depending on dermatosis cli-
nical course in patients with eczema.
Material and methods
An examination  of  92 patients with eczema, inc-
luding 49 men and 43 women, aged from 18 to 59
years old has been carried out.
The criteria for inclusion in the study were the
following: clinical manifestations of eczema; patient's
age - 18 years or more; absence of chronic physical
illnesses  or their exacerbation at the time of the
patient's examination.
According to clinical criteria [3], the majority (63
people - 68.5%) of patients were diagnosed with
microbial eczema, including varicose, and parat-
raumatic and  mycotic ones, the remaining 29
(31.5%) patients had real (true) eczema. In 57
(62.0%) patients with eczema the pathological pro-
cess in the skin was widespread, in 35 (38.0%)  it
was limited. 29 (31.5%) patients with eczema were
diagnosed for the first time, and had acute or suba-
cute clinical course, in 25 (27.2%) it lasted from 1 to
3 years and in 38 (41.3%) - over 3 years. The cont-
rol group involved 35 healthy individuals (donors) of
the same age.
In order to assess the condition of cellular and
humoral immune system in patients with eczema we
determined: relative and absolute number of general
and T- lymphocytes, the relative number of T-helper
(Th) and T-suppressor lymphocytes (Ts) immu-
noregulatory index (Tx/T), relative and the absolute
number of B-lymphocytes, serum immunoglobulin of
(Ig) classes M, G, A and circulating immune comp-
lexes (CIC) by known methods [8].
Statistical analysis of the results of research was
carried out by the methods of statistical analysis [7]
using the computer program Statistica 6.0 the diffe-
rence of averages at p <0.05 was taken as the pro-
bable.
Discussion
In determining the parameters of systemic immu-
nity in 92 patients with eczema, the results of which
are presented in the table, the signs of infectious syn-
drome, mainly reducing T-cell population of lym-
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phocytes were established. Thus, the examined pa-
tients with eczema had probable, compared to in-
dices of the control group, reduction of the absolute
number of common pool of lymphocytes (by 18.2%,
p <0.001), and the relative and absolute number of
common T lymphocytes (by 14.1% and 21.1%, p
<0.001 respectively). However, patients with eczema
experienced some changes in the cell structure of
subpopulations of T- lymphocytes: the likely reduction
in the relative number of T-suppressor lymphocytes
(by 25.4%; p<0.001) with less significant decrease in
the number of T-helper lymphocytes (by 8.4%,
p=0.003) with significant changes of IRI index (inc-
reased by 1.3 times, p=0.007).
The examined patients with eczema also had pro-
bable reduction in the absolute number of lym-
phocytes (23.8%; p<0.001) with a tendency of dec-
reasing their relative amount (by 6.7%; p=0.071).
The analysis of the humoral immune system in pa-
tients with eczema revealed (Table) probable inc-
rease in serum immunoglobulin G (by 15.7%,
p<0.001), immunoglobulin A (by 12.5%, p<0.001)
without significant changes in the level of immu-
noglobulin M. The patients also have significant inc-
rease of CIC in the content of serum (by 10.4%,
p<0,001).
An analysis of systemic immunity indices in pa-
tients with different clinical forms of eczema has
showen that patients suffering from true eczema,
have probable, compared to the control group, dec-
rease in relative and absolute number of T-lympho-
cytes (13.6% and 23.3%, p<0.001 respectively), re-
duction of T-suppressor lymphocytes (by 30.1%,
p<0.001) without significant alteration of T-helper
lymphocytes and significant increase of  CIC in
blood serum (by 12.4%, p<0.001) of Ig G (by 15.7%,
p<0.001)  against a background of a less significant
increase in Ig A (by 11.3%, p=0,01).
Patients with microbial eczema proved to have
probable, compared to the control group, decrease in
relative and absolute number of total T-lymphocytes
(by14.3% and 20.0%, p<0.001 respectively) and its
two subpopulations - T-suppressor (by 20.8%,
p<0.001) and T-helper lymphocytes (by 11.4%,
p<0.001). In addition, these patients had a significant
increase in CIC of serum (by 9.5%, p<0.001), inc-
rease of Ig G (by 15.7%, p<0.001) and Ig A (by
13.1% , p=0.001).
A comparative analysis of systemic immunity in
patients with different clinical forms of eczema detec-
ted some multidirectional changes in their cellular
composition of subpopulations of T-lymphocytes,
more significant reduction in the number of T-supp-
ressor lymphocytes in patients with true eczema
compared to its microbial form (by 11.7%, p=0.012;
11.7±0.522% and 13.4±0.381% respectively), while
patients with microbial eczema had significantly less
T-helper lymphocytes compared with those with true
eczema (by 8.7%, p=0.04; 24.4±0.480% and
26.3±0.844% respectively).
The analysis of systemic immunity indices in pa-
tients with eczema, depending on the area of skin
Table
Systemic immunity indices in patients with eczema
Indices, measurement 
units 
Control group 
(n=35) 
Patients with 
eczema 
(n=92) 
Ð 
 Leucocytes,  g/l 6,33±0,208 5,70±0,099 ð=0,008 
 Lymphocytes,  % 38,1±1,501 35,0±0,704 ð=0,063 
 Lymphocytes, g/l 2,42±0,145 1,98±0,046 ð=0,004 
 Ò-lymphocytes, % 44,1±0,828 37,9±0,410 ð=0,0009 
 Ò-lymphocites, g/l 0,953±0,064 0,752±0,022 ð=0,003 
 Ò-helpers, % 27,3±0,488 25,0±0,431 ð=0,007 
 Ò-suppressors, %  17,3±0,732 12,9±0,317 ð=0,002 
 Immunoregulatory   index   1,68±0,083 2,11±0,086 ð=0,007 
 Â-lymphocytes, %  23,8±0,841 22,2±0,262 ð=0,071 
 Â-lymphocytes, g/l 0,580±0,039 0,442±0,010 ð=0,008 
 Ig À, g/l 1,60±0,041 1,80±0,023 ð=0,004 
 Ig Ì, g/l 1,12±0,062 1,22±0,029 ð=0,15 
 Ig G, g/l 10,2±0,269 11,8±0,184 ð=0,002 
 Circulating immune 
 complex, st.un. 
115,4±2,402 127,4±1,962 ð=0,005 
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lesions found, in patients with advanced skin lesions,
probable reduction in the number of T-suppressor
lymphocytes compared with that of patients with li-
mited process on the skin (by 12.9%, p=0.005;
12.2±0.380% and 14.0±0.509% respectively).
Determination of systemic immunity indices in
patients with eczema, based on the duration of der-
matosis found, in patients with a duration of der-
matosis over 3 years compared with short one (1
year), significantly lower rates of relative (by 10.6%,
p=0.02; 33.0±1.01% and 36.9±1.33% respectively)
and absolute number (by 19.5%, p<0.001; 1.78±0.053
g/l and 2.21±0.099 g/l respectively) of common pool
of lymphocytes, the relative number of T-lympho-
cytes (by 8.2%, p<0.001; 35.9±0.624% and
39.1±0.669% respectively), T-suppressor subpopu-
lation (by 20.3%, p<0.001; 11.4±0.476% and
14.3±0.499% respectively), the absolute number of
B-lymphocytes (by 11.6%, p=0.024; 0.418±0.015 g/l
and 0.473±0.019 g/l respectively) against a backg-
round of CIC increase (by 9.5%, p=0.012;
132.9±3.04% and 121.4±3.21% respectively).
Thus probable changes in systemic immunity in-
dices with signs of  insufficiency of cellular immunity,
mainly after T-cell link. In addition, some multi-
directional changes of subpopulations of T lympho-
cytes were found: in patients with true eczema there
was a reduced number of T-suppressor lymphocytes
which plays an important role in the development and
course of allergic diseases, including skin, and in pa-
tients with microbial forms of dermatosis a significant
reduction of T-helper lymphocytes, which are key
regulators of the immune response, including a
provision of anti-infectious defense, which, in par-
ticular, can explain the development and chronic
course of microbial forms of eczematous process in
the skin.
A probable decline in cellular link indices of sys-
temic immunity in patients with prolonged (over three
years) clinical course of dermatosis against a back-
ground of CIC that are able to detect damaging ef-
fect on the vascular endothelium, cell membranes,
thereby strengthening exudative manifestations and
chronic inflammatory processes in the areas of skin
inflammation is a confirmation of sufficient role of
immune mechanisms in the pathogenesis of eczema.
The obtained study results suggest immunodepen-
dent nature of the development of skin eczematous
process and the necessity to administer a rational
immunocorrective therapy for such patients.
Conclusions
1. Patients with eczema experienced significant
changes in systemic immunity indexes which indicate
the presence of secondary insufficiency, mainly T-
cell link, with multi-directional changes in subpo-
pulations of T- lymphocytes in patients with different
clinical forms of dermatitis.
2. Some more significant changes in systemic
immunity indices were established in patients with
advanced eczema skin and prolonged (over 3 years)
course of dermatosis that justifies advisability of ade-
quate immunocorrective therapy for these patients.
Prospects for further research
We are going to develop and evaluate the clinical
effect of the combined treatment of patients with
eczema by administering immunocorrective therapy
for such patients.
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ÏÎÊÀÇÍÈÊÈ ÑÈÑÒÅÌÍÎÃÎ ²ÌÓÍ²ÒÅÒÓ Ó
ÕÂÎÐÈÕ ÍÀ ÅÊÇÅÌÓ Ç Ð²ÇÍÈÌ ÊË²Í²×ÍÈÌ
ÏÅÐÅÁ²ÃÎÌ
Í.À. Ñòåïàí, Î.². Äåíèñåíêî
Ðåçþìå. Ó õâîðèõ íà åêçåìó âñòàíîâëåíî â³ðîã³äí³ çì³íè
ïîêàçíèê³â ñèñòåìíîãî ³ìóí³òåòó, ÿê³ ñâ³ä÷àòü ïðî íàÿâí³ñòü
³ìóíîîïîñåðåäêîâàíèõ ìåõàí³çì³â ðîçâèòêó åêçåìè ïåðå-
âàæíî ³ç çàëó÷åííÿì Ò-ëàíêè ³ìóí³òåòó, ç ð³çíîñï-
ðÿìîâàíèìè çì³íàìè ñóáïîïóëÿö³é Ò-ë³ìôîöèò³â ó õâîðèõ íà
ð³çí³ êë³í³÷í³ ôîðìè äåðìàòîçó. Âñòàíîâëåíî, ùî á³ëüø
³ñòîòí³ çì³íè ïîêàçíèê³â ñèñòåìíîãî ³ìóí³òåòó ðåºñòðóþòüñÿ
ó õâîðèõ íà åêçåìó ç ïîøèðåíèì óðàæåííÿì øê³ðè òà
òðèâàëèì (á³ëüøå 3 ðîê³â) ïåðåá³ãîì äåðìàòîçó, ùî îáãðóí-
òîâóº äîö³ëüí³ñòü ïðèçíà÷åííÿ òàêèì ïàö³ºíòàì àäåêâàòíî¿
³ìóíîêîðèãóþ÷î¿ òåðàï³¿.
Êëþ÷îâ³ ñëîâà: åêçåìà, êë³í³÷íèé ïåðåá³ã, ñèñòåìíèé
³ìóí³òåò.
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ÏÎÊÀÇÀÒÅËÈ ÑÈÑÒÅÌÍÎÃÎ ÈÌÌÓÍÈÒÅÒÀ Ó
ÁÎËÜÍÛÕ ÝÊÇÅÌÎÉ Ñ ÐÀÇÍÛÌ ÊËÈÍÈ×ÅÑÊÈÌ
ÒÅ×ÅÍÈÅÌ
Í.À. Ñòåïàí, Î.È. Äåíèñåíêî
Ðåçþìå. Ó áîëüíûõ ýêçåìîé óñòàíîâëåíû äîñòîâåðíûå
èçìåíåíèÿ ïîêàçàòåëåé ñèñòåìíîãî èììóíèòåòà, êîòîðûå
ñâèäåòåëüñòâóþò î íàëè÷èè èììóíîîïîñðåäîâàííûõ ìåõà-
íèçìîâ ðàçâèòèÿ åêçåìè ïðåèìóùåñòâåííî ñ âîâëå÷åíèåì Ò-
çâåíà èììóíèòåòà, ñ ðàçíîíàïðàâëåííûìè èçìåíåíèÿìè
ñóáïîïóëÿöèé Ò-ëèìôîöèòîâ ó áîëüíûõ ðàçíûìè êëèíè-
÷åñêèìè ôîðìàìè äåðìàòîçà. Óñòàíîâëåíî, ÷òî áîëåå ñó-
ùåñòâåííûå èçìåíåíèÿ ïîêàçàòåëåé ñèñòåìíîãî èììóíèòåòà
ðåãèñòðèðóþòñÿ ó áîëüíûõ ýêçåìîé ñ ðàñïðîñòðàíåííûì
ïîðàæåíèåì êîæè è äëèòåëüíûì (áîëüøå 3 ëåò) òå÷åíèåì
äåðìàòîçà, ÷òî îáîñíîâûâàåò öåëåñîîáðàçíîñòü íàçíà÷åíèÿ
òàêèì ïàöèåíòàì àäåêâàòíîé èììóíîêîððåãèðóþùåé
òåðàïèè.
Êëþ÷åâûå ñëîâà: ýêçåìà, êëèíè÷åñêîå òå÷åíèå, ñèñ-
òåìíûé èììóíèòåò.
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